SG

Sushil Gangaram Rane

Director Director DIN 02720548
DIN 02720548 First appointment Apr 2009 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Apr 2009
Shareholding value •••• Premium profile

About Sushil Gangaram Rane

Data last updated:

Sushil Gangaram Rane was a Director at Franco-Indian Pharmaceuticals Private Limited (2009–2012) and Director at Wardex Pharmaceuticals Private Limited (2009–2012). The companies operate in Pharma.

DIN 02720548
Primary Designation Director
Industry Pharma
First Appointment 29 Apr 2009

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director29 Apr 20091959₹989 Cr (FY 2024)Active
Director30 Sep 20091946₹158 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Franco-Indian Pharmaceuticals Private Limited
Wardex Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Sushil Gangaram Rane

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sushil Gangaram Rane

Sushil Gangaram Rane was first appointed on 29 Apr 2009 as Director at Franco-Indian Pharmaceuticals Private Limited.

Sushil Gangaram Rane held 2 earlier board appointments: Franco-Indian Pharmaceuticals Private Limited (Director, 29 Apr 2009 to 03 Sep 2012); Wardex Pharmaceuticals Private Limited (Director, 30 Sep 2009 to 01 Sep 2012).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available